<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226574</url>
  </required_header>
  <id_info>
    <org_study_id>RTX-001</org_study_id>
    <nct_id>NCT03226574</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain</brief_title>
  <official_title>A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult
      subjects with intractable pain associated with cancer in any area below the mid-thoracic
      level who meet all other eligibility criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects who received RTX will be included in the analyses and summaries of safety,
      efficacy, PD, and PK assessments.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">March 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The design uses a traditional &quot;3+3&quot; rule-based design that does not stipulate any prior assumption of the dose-toxicity curve. Dose escalation is permitted between successive cohorts based upon a specified algorithm, using discrete dosage steps.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>3-month</time_frame>
    <description>Grade 3 or 4 Toxicity associated with RTX administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>3-month</time_frame>
    <description>Maximum dose without a Grade 3 or 4 toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric Pain Rating Scale (NPRS)</measure>
    <time_frame>Day-28 to Day90 daily</time_frame>
    <description>Daily average pain and daily worst pain on a 0-10 scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Daily analgesic consumption (DAC) log</measure>
    <time_frame>Day-28 to Day90 daily</time_frame>
    <description>Consumption of analgesics compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief Pain Inventory-Short Form (BPI-SF)</measure>
    <time_frame>Day-28, Day1, Day2/3, Day8, Day15, Day30, Day60 and Day90</time_frame>
    <description>Quality of life compared to baseline by the total score</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Day2/3, Day8, Day15, Day30, Day60 and Day90</time_frame>
    <description>Patient-reported rating of improvement on a 7-point scale, ranking the improvement from (1) to (7), with (1) being no change or worse to (7) being a great deal better and a considerable improvement that has made all the difference.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Numeric Pain Rating Scale (modified NPRS)</measure>
    <time_frame>Day1, Day2/3, Day8, Day15, Day30, Day60 and Day90</time_frame>
    <description>A 11-point scale for rating average and worst pain at the location intended to be treated with RTX within 12 hours of the clinical visit, with 0 being no pain to 10 being worst pain imaginable.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Brief Pain Inventory-Short Form (modified BPI-SF)</measure>
    <time_frame>Day1, Day2/3, Day8, Day15, Day30, Day60 and Day90</time_frame>
    <description>Quality of life affected by pain at the location intended to be treated with RTX, each question rates pain level and pain interference on a 0 to 10 scale. For pain level questions, 0 represents no pain and 10 represents pain as bad as can be imagined. For pain interference questions, 0 is &quot;does not interfere&quot; and 10 is &quot;completely interferes&quot;.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Intractable Cancer Pain</condition>
  <arm_group>
    <arm_group_label>RTX epidural injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiniferatoxin</intervention_name>
    <description>single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection</description>
    <arm_group_label>RTX epidural injection</arm_group_label>
    <other_name>RTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced cancer or metastasis, which has not responded to
             standard therapy, producing intractable chronic pain in any area below the
             mid-thoracic level.

          -  Male or female subjects must be at least 18 years of age.

          -  Must have a worst pain score ≥6 on the NPRS at Screening visit.

          -  Subjects not seeking or receiving potentially curative therapies for cancer.
             Palliative therapy is acceptable if the therapy started and is stable prior to IP
             administration.

          -  Sexually active female subjects of childbearing potential and male subjects capable of
             fathering a child must be willing to use an effective method of contraception to avoid
             pregnancies.

          -  Must be willing and capable of understanding and cooperating with the requirements of
             the study.

          -  Must be able to understand and complete study-related forms and adequately communicate
             with the investigator and/or site staff.

          -  Must have provided written informed consent prior to participating in any
             study-related activity.

          -  Subjects able to complete the study duration.

        Exclusion Criteria:

          -  Subjects with leptomeningeal metastases in lumbar area.

          -  Undergoing or have plans to undergo changes to current cancer treatment during the
             study through the Day15 assessment.

          -  Had prior lumbar spine surgical procedures that could impair the ability to perform
             the injection.

          -  Evidence of brain pathology or increase intracranial pressure.

          -  Presence of an IT shunt.

          -  Has evidence or a coagulopathy or hemostasis problem.

          -  Subjects with a total neutrophil count &lt;1500 cells/mm3.

          -  Subjects with serum creatinine ≥1.5 mg/dL.

          -  Is febrile or has other evidence of an infection within 7 days of planned injection.

          -  Has an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic
             contrast agents.

          -  Female subjects who are pregnant, are planning on becoming pregnant, or are currently
             breastfeeding.

          -  Subjects with any medical condition that could adversely impact study participation or
             assessments.

          -  Subjects who have received new anti-cancer treatments and there is less than one week
             or four half-lives of the investigational drug, whichever is greater, between the last
             dose of the new drug and the planned day of IP administration; or had a change in the
             dose or schedule of the anti-cancer treatments within one week or four half-lives,
             whichever is greater, between the last dose of the anti-cancer treatment and the
             planned day of IP administration; or are scheduled to receive a new anti-cancer
             therapy or investigational product prior to completion of the Day 15 visit.

          -  Subjects with additional loci of pain above the mid-thoracic level or other pain
             disorder due to non-cancer etiology, unless both the investigator and the subject are
             clearly able to distinguish the additional pain from the target pain due to cancer.

          -  Liver cirrhosis or severe hepatic impairment, with liver function test 3 times above
             ULN.

          -  Sensory/peripheral neuropathy of CTCAE Grade 2 or higher.

          -  Nonstudy related minor surgical procedure ≤5 days or major surgical procedure ≤21 days
             prior to Screening visit.

          -  Subjects who have not completely recovered from any toxicities from previous
             chemotherapy, hormone therapy, immunotherapy, or radiotherapies that are CTCAE Grade 3
             or higher.

          -  Arterial thrombi (including stroke), myocardial infarction, admission for unstable
             angina, cardiac angioplasty, or stenting within 3 months prior to Screening visit.

          -  Corrected QT using Fridericia's formula (QTcF) prolongation.

          -  Evidence or history of bleeding disorder within 4 weeks prior to IP administration.

          -  Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of
             chronic hepatitis B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Luchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami/Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resiniferatoxin</keyword>
  <keyword>RTX</keyword>
  <keyword>Cancer pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

